feedback

Course Director

Jonathan E. Rosenberg, MD
Jonathan E. Rosenberg, MD

Memorial Sloan Kettering Cancer Institute
New York, New York

Faculty

Hans Hammers
Hans Hammers, MD, PhD

UT Southwestern Medical Center
Dallas, Texas

Ravi A. Madan
Ravi A. Madan, MD

Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Mar-22
Expiration Date:2019-Mar-21
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

In this activity, based on a recent symposium at the American Society of Clinical Oncology’s 2018 Genitourinary Cancers Symposium (ASCO GU 2018), experts in oncology discuss how the era of immune-oncology (IO) has changed the optimal management of genitourinary cancers with the approval of checkpoint inhibitors for renal cell carcinoma (RCC) and bladder cancer. In RCC, checkpoint inhibition provides additional options for recurrent disease, while combination therapy is poised to move into the frontline. For bladder cancer, checkpoint inhibitors are altering the standard of care in both first- and second-line therapy, with IO in earlier stage disease being evaluated. In prostate cancer, intriguing IO data are emerging for subsets of patients. The rapid pace of new evidence and drug approvals challenges clinicians to fully understand how to use these agents safely and to optimize their placement within the treatment paradigm for each disease.

Upon completion of this activity, participants should be better able to:

  • Cite the current unmet medical needs in GU cancers
  • Explain the mechanisms of action and relevant pathways of immunotherapy
  • Describe immuno-oncologic cancer treatments and response to treatment including pseudoprogression/nonconventional response kinetics
  • Differentiate between the safety profiles of conventional and immuno-oncologic cancer treatments
  • Manage toxicities of both conventional and immuno-oncologic treatments
  • Describe the clinical profiles of currently available and emerging immuno-oncologic agents based on overall survival, durability of response, and the improved safety and tolerability of these agents

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, oncology advanced practitioners, and other clinicians involved in the management of GU cancers.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2018 - March 21, 2019
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Jonathan E. Rosenberg, MD
Medical Oncologist
Enno W. Ercklentz Chair
Memorial Sloan Kettering Cancer Institute
New York, New York

Jonathan E. Rosenberg, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Agensys, Inc.; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; Eli Lilly and Company; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc.
Other Financial or Material Support from AstraZeneca and Merck & Co., Inc. for speaking fees.

Jonathan E. Rosenberg, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various targeted agents, immune checkpoint inhibitors, vaccines, and combinations of such agents in genitourinary cancers.

Faculty

Hans Hammers, MD, PhD
Associate Professor
UT Southwestern Medical Center
Kidney Cancer Program
Department of Internal Medicine
Division of Hematology and Oncology
Dallas, Texas

Hans Hammers, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb; Eisai Inc.; and Novartis Pharmaceuticals Corporation.
Grant/Research Support from Bristol-Myers Squibb and Merck & Co., Inc.

Hans Hammers, MD, PhD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various targeted agents, immune checkpoint inhibitors, vaccines, and combinations of such agents in genitourinary cancers.

Ravi A. Madan, MD
Clinical Director
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health​
Bethesda, Maryland

Ravi A. Madan, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Boehringer Ingelheim Pharmaceuticals, Inc. Spouse is on Speakers Bureau of Janssen Pharmaceuticals, Inc. and Pfizer Inc.

Ravi A. Madan, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various targeted agents, immune checkpoint inhibitors, vaccines, and combinations of such agents in genitourinary cancers.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through an educational grant from Bristol-Myers Squibb.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.